Interstitial Granulomatous Dermatitis (IGD)

Interstitial granulomatous dermatitis (IGD) is an uncommon skin condition that consists of skin inflammation and has unique histopathological features including a complex inflammatory dermal infiltrate of histiocytes and neutrophils formed within the dermis interstitially, which often lacks clearly defined granulomas. Protheragen offers end-to-end preclinical drug and therapy development services that confront the specific challenges posed by interstitial granulomatous dermatitis.

Introduction to Interstitial Granulomatous Dermatitis

Interstitial Granulomatous Dermatitis (IGD) is considered a rare condition, immune-mediated in nature, with the following cutaneous manifestations: erythematous plaques, annular lesions along with a characteristic rope-like cords pattern. Histopathology findings include dermal granulomatous infiltrates along with collagen degeneration. It is estimated that only 0.5–1 per 100,000 individuals affected. However, it is more common than diagnosed due to being overlooked because of the overlapping histopathology with sarcoidosis and palisaded neutrophilic granulomatous dermatitis.

Pathogenesis of Interstitial Granulomatous Dermatitis

It is widely accepted that Interstitial Granulomatous Dermatitis (IGD) develops as an autoimmune disorder which usually accompanies another systemic disease that turns on a specific pathogenic process involving disproportionate immune system response localized in the skin. The hallmark feature consists of activated Histiocytes along with neutrophils interstitially infiltrating the dermis through walls, which in turn seem to be driven by many inflammatory cytokines like TNF-α as well as IFN-γ. Therefore, it can be speculated that reactive cutaneous inflammation arising from more extensive systemic inflammation or immune dysregulation primarily drives IGD pathology.

Fig.1 H&E histopathology of left forearm skin punch biopsy. (Starling et al., 2022)

Therapeutics Development for Interstitial Granulomatous Dermatitis

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen has the ability to provide complete services to advance the therapy for IGD. Our expert scientists, dermatologists, and geneticists use advanced technology to enable progress in focused therapeutic development and disease model development services to support your initiatives.

Therapeutic Development Platforms for Interstitial Granulomatous Dermatitis

Disease Models Development for Interstitial Granulomatous Dermatitis

Protheragen offers a comprehensive provision of preclinical models to facilitate your IGD translational applied research with advanced platforms of both 2D cell models, 3D skin models, and animal models development, which are all ready to model the disease-specific pathologies to expedite therapeutic development.

2D Cell Models & 3D Skin Models

• Patient-Derived Macrophages/Histiocytes
• Fibroblast-Immune Cell Co-culture Systems
• 3D Reconstructed Human Skin Models

Animal Models Development

• HLA-DR4^tg Spontaneous Granulomatosis Mice
• Humanized IGD Xenograft NSG Mice
• TNF-α^ΔKER Inducible Model
• TNF-α Overexpression or Transgenic Mice

Drug Safety Evaluation & DMPK Services